Acuitas Therapeutics v. Alnylam Pharmaceuticals: LNP Patent Suit Dismissed on Standing
Acuitas Therapeutics filed a six-patent infringement action against Alnylam Pharmaceuticals in Delaware over lipid nanoparticle technology used in mRNA-LNP drug products. The court dismissed the complaint without prejudice after finding Acuitas lacked Article III constitutional standing — a threshold ruling that left the merits entirely unresolved after 410 days of litigation.
LNP patent clash ends on standing, not merits, in Delaware
On July 12, 2024, Acuitas Therapeutics, Inc. filed a patent infringement complaint against Alnylam Pharmaceuticals, Inc. in the United States District Court for the District of Delaware (Case No. 1:24-cv-00816), presided over by Judge Colm F. Connolly. The suit asserted six U.S. patents — US11590229B2, US11246933B1, US11633479B2, US11612657B2, US11382979B2, and US11633480B2 — all directed to lipid nanoparticle (LNP) delivery technology central to mRNA-based drug products.
On July 1, 2025, Judge Connolly granted in part Alnylam’s Rule 12(b)(1) motion to dismiss, finding that Acuitas lacked Article III constitutional standing to assert the patents. The complaint was dismissed without prejudice, meaning the substantive infringement and validity questions were never reached. Acuitas retained the right to refile should it cure the standing deficiency — for example, by joining a necessary party or establishing its ownership or exclusive licensee status more clearly on the record.
The 410-day duration — from filing to dismissal — is consistent with the time typically consumed by briefing on a motion to dismiss in Delaware. The standing dismissal suggests the public record may be silent on whether Acuitas holds all substantial rights in the six patents or whether a co-owner or licensor failed to join the suit. What drove the specific Article III defect remains outside the public docket summary, and whether Acuitas will refile with corrected standing is unknown.
Filing to Dismissed without Prejudice in 410 days
410 days — above median for a standing-based dismissal in Delaware District Court
Dismissed without prejudice: what the standing ruling means for both parties
Article III standing dismissed the case before any merits ruling
A Rule 12(b)(1) dismissal for lack of Article III standing means the court lacked subject-matter jurisdiction to hear the dispute. The judge found Acuitas failed to demonstrate a sufficient legal interest in the asserted patents to constitute a ‘case or controversy’ under the U.S. Constitution. Critically, no infringement or validity finding was made — Alnylam’s products were never adjudicated as infringing or non-infringing.
Jurisdictional — no merits reachedWithout prejudice leaves Acuitas a path to refile
Dismissal without prejudice does not bar Acuitas from bringing the same claims again. To refile successfully, Acuitas would need to cure whatever standing defect the court identified — typically by joining all co-owners, securing a more explicit assignment, or restructuring its licensing arrangement to confer all substantial rights. The six LNP patents remain in force and enforceable by a party with proper standing.
Refile option preservedAlnylam wins dismissal but faces continued LNP patent risk
Alnylam secured dismissal without any merits determination in its favour. Because the dismissal is without prejudice, Alnylam cannot rely on this order as a bar to future litigation over the same patents. The company remains exposed to a refiled action if Acuitas corrects its standing posture. Alnylam’s mRNA-LNP products continue to face potential infringement exposure from these six patents.
No merits immunity grantedLNP IP uncertainty persists for the mRNA therapeutics sector
The standing dismissal leaves the validity and scope of Acuitas’s six LNP patents unresolved. For companies developing or licensing mRNA-LNP platforms — including COVID-19 vaccines and RNA interference therapies — this outcome suggests the dispute is not over. Freedom-to-operate analyses referencing these patents remain relevant, and deal teams structuring LNP licensing agreements should monitor whether a refiled action emerges.
LNP IP risk unresolvedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Acuitas Therapeutics, Inc. | Company | Biopharmaceutical LNP technology licensor — holder of US11590229B2 and five related LNP patentsSearch in Eureka ↗ |
| Defendant | Alnylam Pharmaceuticals, Inc. | Company | Alnylam Pharmaceuticals, Inc. — leading RNA interference therapeutics companySearch in Eureka ↗ |
| Plaintiff counsel | Allison C. Penfield | Attorney | Counsel for Acuitas Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Ariella Barel | Attorney | Counsel for Acuitas Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Catherine Lynch | Attorney | Counsel for Acuitas Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Chih-wei Wu | Attorney | Counsel for Acuitas Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Eric A. Stone | Attorney | Counsel for Acuitas Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | James L. Higgins | Attorney | Counsel for Acuitas Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Josephine Young | Attorney | Counsel for Acuitas Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Melanie K. Sharp | Attorney | Counsel for Acuitas Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Nicholas Groombridge | Attorney | Counsel for Acuitas Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Nisha Gera | Attorney | Counsel for Acuitas Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Saurabh Gupta | Attorney | Counsel for Acuitas Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Stephanie Vangellow | Attorney | Counsel for Acuitas Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Young Conaway Stargatt & Taylor, LLP | Law Firm | Representing Acuitas Therapeutics, Inc.Search in Eureka ↗ |
| Defendant counsel | David J. Tobin | Attorney | Counsel for Alnylam Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Ethan Haller Townsend | Attorney | Counsel for Alnylam Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Mandy H. Kim | Attorney | Counsel for Alnylam Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Sarah Chapin Columbia | Attorney | Counsel for Alnylam Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | William G. Gaede , III | Attorney | Counsel for Alnylam Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | McDermott Will & Schulte LLP | Law Firm | Representing Alnylam Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The July 1, 2025 order reflects a split ruling: the court denied dismissal under Rule 12(b)(1) for failure to comply with 35 U.S.C. § 256 — meaning the inventorship-correction argument did not eliminate standing — but granted dismissal on Article III constitutional grounds. Rendering the remaining 12(b)(6) arguments moot signals the court found the jurisdictional defect dispositive without needing to assess whether the complaint stated a viable infringement claim. The without-prejudice designation preserves Acuitas’s litigation options but places the burden of curing the constitutional defect squarely on the plaintiff.
US11590229B2 and five co-asserted LNP delivery patents
The six asserted patents — US11590229B2, US11246933B1, US11633479B2, US11612657B2, US11382979B2, and US11633480B2 — are directed to lipid nanoparticle (LNP) compositions and methods used to encapsulate and deliver mRNA and other nucleic acid payloads into cells. LNP technology is the primary delivery vehicle enabling mRNA therapeutics and RNA interference drugs, including SARS-CoV-2 vaccines and siRNA-based medicines. The application numbers suggest these patents were prosecuted across multiple related application filings in the US17/6xx series, consistent with a family of continuation or divisional applications protecting different aspects of the same core LNP platform.
Acuitas is widely recognised as a key licensor of LNP technology to major pharmaceutical developers, having supplied LNP formulations used in approved COVID-19 mRNA vaccines. The six patents asserted against Alnylam — a dominant player in RNA interference therapeutics — suggest a dispute over whether Alnylam’s commercial LNP formulations fall within Acuitas’s patent claims. Given the breadth of the LNP patent landscape and Alnylam’s deep pipeline of siRNA products delivered via lipid nanoparticles, the commercial stakes of any successful refiling are significant for both parties and the broader mRNA-LNP licensing ecosystem.
Should you run an FTO against US11590229B2 and the Acuitas LNP patent family?
Any company developing, manufacturing, or licensing mRNA therapeutics, siRNA drugs, or nucleic acid vaccines that use lipid nanoparticle delivery systems should treat these six Acuitas patents as live freedom-to-operate risks. The without-prejudice dismissal means no court has invalidated or narrowed any of these claims — they remain fully enforceable against any party with proper standing to sue. Product teams building LNP-based delivery platforms and deal teams structuring mRNA licensing agreements need current FTO coverage against this patent family.
PatSnap Eureka’s FTO Search Agent enables rapid claim-level mapping of US11590229B2 and its five co-asserted patents against your specific product formulations. Eureka identifies prior art, claim scope boundaries, and related family members across jurisdictions — helping R&D and IP teams assess design-around options and licensing exposure before a refiled Acuitas action reaches the merits stage. Set up automated monitoring to receive alerts if new continuation filings or a refiled complaint appears in the public record.
Run a freedom-to-operate analysis on US11590229B2 to assess your product’s exposure
Run FTO in Eureka →Similar LNP and mRNA delivery patent cases in Delaware and CAFC
Cases involving lipid nanoparticle and mRNA delivery technology patent disputes in Delaware District Court and related appellate proceedings.
What this case signals for the mRNA-LNP IP landscape
A standing dismissal in a six-patent LNP case is a procedural pause, not a resolution — and the sector should treat it as such.
Standing defects are a growing attack vector in platform technology licensing
Where foundational technologies like LNP delivery systems change hands through complex licensing and assignment chains, standing vulnerabilities accumulate. Alnylam’s successful 12(b)(1) motion suggests meticulous review of patent ownership records before filing is essential — co-owner joinder failures are difficult to cure after dismissal.
Without-prejudice dismissals reset the clock, not the risk
Alnylam’s product line is not cleared. The six asserted LNP patents remain active, and Acuitas retains the right to refile. Companies licensing or building on Alnylam’s mRNA-LNP platform should maintain patent monitoring on US11590229B2 and its five co-asserted patents pending any refiled action.
Acuitas v Alnylam — key questions answered
Judge Connolly dismissed the complaint on July 1, 2025 because Acuitas lacked Article III constitutional standing to assert the six LNP patents. The court granted Alnylam’s Rule 12(b)(1) motion on standing grounds while denying the 35 U.S.C. § 256 inventorship argument. Dismissal without prejudice means Acuitas may refile if it cures the standing deficiency.
Acuitas asserted six U.S. patents: US11590229B2, US11246933B1, US11633479B2, US11612657B2, US11382979B2, and US11633480B2. All relate to lipid nanoparticle delivery technology used in mRNA and nucleic acid drug products, and appear to form a related patent family based on their application numbers.
Article III standing requires a plaintiff to have a sufficient legal interest in the asserted patents — typically ownership or an exclusive licence conveying all substantial rights. Without standing, the federal court lacks subject-matter jurisdiction and cannot adjudicate the merits. Common causes include co-owner failure to join the suit or an incomplete assignment chain.
Yes. A dismissal without prejudice does not bar refiling. Acuitas would need to cure whatever standing defect the court identified — for example, by joining all patent co-owners or obtaining a more complete assignment — and then file a new complaint. The six asserted patents remain enforceable in any such refiled action.
Alnylam is a leading developer of RNA interference therapeutics, many of which rely on LNP delivery systems. The six Acuitas patents cover LNP compositions and methods central to mRNA and nucleic acid drug delivery. If the infringement claims survive a refiled action, they could affect Alnylam’s ability to commercialise its siRNA pipeline without a licence from Acuitas.
PatSnap Eureka searches patents and litigation data to answer instantly.